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Abstract
Objective: A subset analysis of the randomised, phase 3, MDS-004 study to evaluate outcomes in patients
with International Prognostic Scoring System (IPSS)-defined Low-/Intermediate (Int)-1-risk myelodysplastic
syndromes (MDS) with isolated del(5q). Methods: Patients received lenalidomide 10 mg/d (days 1–21;
n = 47) or 5 mg/d (days 1–28; n = 43) on 28-d cycles or placebo (n = 45). From the placebo and
lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over to lenalidomide 5 or
10 mg at 16 wk, respectively. Results: Rates of red blood cell-transfusion independence (RBC-TI) ≥182 d
were higher in the lenalidomide 10 mg (57.4%; P < 0.0001) and 5 mg (37.2%; P = 0.0001) groups vs.
placebo (2.2%). Cytogenetic response rates (major + minor responses) were 56.8% (P < 0.0001), 23.1%
(P = 0.0299) and 0%, respectively. Two-year cumulative risk of acute myeloid leukaemia progression was
12.6%, 17.4% and 16.7% in the lenalidomide 10 mg, 5 mg, and placebo groups, respectively. In a
6-month landmark analysis, overall survival was longer in lenalidomide-treated patients with RBC-TI ≥182 d
vs. non-responders (P = 0.0072). The most common grade 3–4 adverse event was myelosuppression.
Conclusions: These data support the clinical benefits and acceptable safety profile of lenalidomide in
transfusion-dependent patients with IPSS-defined Low-/Int-1-risk MDS with isolated del(5q).
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Deletions of the long arm of chromosome 5 [del(5q)] are
present in approximately 10–15% of patients with primary
myelodysplastic syndromes (MDS) (1, 2), and del(5q) is one
of the most frequently occurring cytogenetic aberrations in
MDS (1–4). In approximately 80% of the patients with Inter-
national Prognostic Scoring System (IPSS)-defined Low- or
Intermediate (Int)-1-risk disease who present with the del
(5q) abnormality, del(5q) is the only cytogenetic abnormality
[isolated del(5q)] (5, 6). MDS with isolated del(5q) and
<5% bone marrow blasts are considered a distinct clinical
entity in the World Health Organization classification system
(7) and are characterised by a favourable prognosis (1, 3, 4,
8–10). However, most patients with MDS and del(5q) even-
tually require red blood cell (RBC) transfusions (11), and
RBC-transfusion dependence has been linked to poor prog-
nosis in these patients (5).
In the phase 3, randomised, double-blind, placebo-con-
trolled, multicentre study MDS-004, the efficacy and safety
of lenalidomide were assessed in RBC-transfusion-dependent
patients with IPSS-defined Low- or Int-1-risk MDS and del
(5q), with or without additional cytogenetic abnormalities
(12). Results of the primary study have been previously
reported (12).
Lenalidomide was recently approved in the European
Union for the treatment of patients with transfusion-depen-
dent anaemia because IPSS-defined Low- or Int-1-risk MDS
associated with an isolated del(5q) cytogenetic abnormality,
when other therapeutic options are insufficient or inadequate.
This post hoc analysis evaluated treatment responses, acute
myeloid leukaemia (AML) progression, overall survival
(OS) and adverse events in a subset of patients from the
MDS-004 study who had isolated del(5q) [defined].
Methods
This retrospective subset analysis of the MDS-004, phase 3,
randomised, double-blind, placebo-controlled trial analysed
patients with RBC-transfusion-dependent, IPSS-defined
Low- or Int-1-risk MDS with isolated del(5q). Full method-
ology for the MDS-004 study has been described previously
(12). Briefly, transfusion dependence was defined as no per-
iod of eight consecutive weeks without RBC transfusions
within 16 wk before randomisation. Risk was assessed
according to the IPSS. Bone marrow pathology and del(5q)
status were confirmed by central haematological and cytoge-
netic review after randomisation. Patients were excluded if
they had any of the following: proliferative (white blood cell
count ≥12 000/lL) chronic myelomonocytic leukaemia;
grade ≥2 neuropathy; prior use of lenalidomide; prior use of
recombinant erythropoietin, chemotherapy or treatment with
any other investigational agent within the past 28-d or long-
acting erythropoiesis-stimulating agents within the past
8 wk; or abnormal laboratory values (absolute neutrophil
count <500/lL, platelet count <25 000/lL, serum creatinine
>2.0 mg/dL, serum transaminases >3.0 9 upper limit of
normal and serum total bilirubin >1.5 mg/dL). All patients
provided written informed consent. The study was approved
by individual Institutional Review Boards at participating
treatment centres and was conducted according to the Decla-
ration of Helsinki.
Treatment in the double-blind and open-label
extension phases
Patients were randomised 1 : 1 : 1 to oral lenalidomide
10 mg on days 1–21 or lenalidomide 5 mg on days 1–28 of
each 28-d cycle or placebo. Erythroid response was assessed
at 16 wk. Patients with at least a minor erythroid response
continued double-blind treatment for up to 52 wk or until
relapse, disease progression or unacceptable toxicity. Patients
who completed the 52-wk-double-blind treatment phase
without disease progression or erythroid relapse were
unblinded and continued study treatment in the open-label
extension phase at their current dose. Patients who did not
achieve at least a minor erythroid response discontinued
double-blind treatment and entered the open-label extension
phase or were withdrawn from the study. Patients without a
minor erythroid response or erythroid relapse in the placebo
group were eligible to receive lenalidomide 5 mg in the
open-label extension phase; those in the lenalidomide 5 mg
group could receive lenalidomide 10 mg; and those in the
10 mg group were withdrawn from the study. Patients
received a maximum of 156 wk of total study treatment.
Use of granulocyte colony-stimulating factor and granulo-
cyte-macrophage colony-stimulating factors was allowed for
treatment of neutropenia. Thromboprophylaxis was not man-
dated.
Study endpoints and statistical methods
The primary endpoint of the study was RBC-transfu-
sion independence (RBC-TI) ≥182 d. Secondary endpoints
included duration of RBC-TI ≥182 d, time to RBC-TI
≥182 d, cytogenetic response, OS, AML progression and
safety. Change in haemoglobin level from baseline was also
assessed.
The Kaplan–Meier method was used to analyse duration
of RBC-TI, and data are included until the last date with
available information on transfusions. For patients who lost
RBC-TI response, duration of RBC-TI was defined as the
time between last transfusion before the start of the transfu-
sion-independent period or the first dose of study drug
(whichever occurred later) and the first transfusion after the
transfusion-independent period; this loss of RBC-TI response
was counted as an ‘event’ in statistical analyses of time-to-
event variables. For patients who remained RBC-transfusion
independent, the duration of RBC-TI was calculated as the
time between last transfusion before the start of the
430 © 2014 The Authors. European Journal of Haematology Published by John Wiley & Sons Ltd.
Lenalidomide in isolated del(5q) MDS Giagounidis et al.
transfusion-independent period or the first dose of study
drug (whichever occurred later) and the last data collection
date on RBC transfusion; this was censored in time to event
analyses.
Cytogenetic response reflects best postbaseline response,
assessed using International Working Group 2000 criteria
(13) and based on karyotyping results (≥20 metaphases)
and fluorescence in situ hybridisation. Time to AML
progression and death was calculated from the time of
randomisation; AML was diagnosed according to the
French-American-British criteria (14), and time to death was
calculated as time to death from any cause. Adverse events
were coded using Medical Dictionary for Regulatory Activi-
ties version 13.0 and graded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events, version 3.0. Safety and efficacy were evaluated
throughout the study, and bone marrow aspirates and cytoge-
netic assessments to monitor disease progression were
performed at baseline, 12 and 24 wk and every 24 wk there-
after. Bone marrow aspirates were submitted and assessed by
central pathology and cytogenetics review. Descriptive statis-
tics were used to compare the lenalidomide 10 and 5 mg
groups separately against placebo. Duration of response,
AML progression and OS was characterised using Kaplan–
Meier curves with differences evaluated by the log-rank test.
Patients who discontinued the study for any reason were fol-
lowed up for OS and progression to AML. To minimise bias,
6-month landmark analyses (excluding all early events that
occurred in the first 6 months) were performed in patients
randomised to lenalidomide to analyse AML progression and
OS according to RBC-TI ≥182 d response (responders vs.
non-responders) and cytogenetic response (responders vs.
non-responders).
For patients assigned to lenalidomide treatment, univari-
ate and multivariate logistic regression models were built
to identify independent factors associated with RBC-TI
≥182 d response. Univariate and multivariate Cox propor-
tional hazards models were built to identify independent
factors associated with OS and time to AML progression.
Firstly, univariate models were built to identify important
independent variables associated with dependent outcome.
Secondly, all significant variables identified by univariate
analysis with P < 0.15 were used as initial variables in the
multivariate models. Finally, a backward-elimination vari-
able-selection approach was used to build the final multi-
variate models. The following baseline variables were
evaluated: age (years), time since MDS diagnosis (years),
RBC-transfusion burden (units/8 wk), bone marrow blast
count (≥5% vs. <5%), number of cytopenias (2–3 vs. 1),
platelet count (9109/L), absolute neutrophil count (9109/
L), haemoglobin (g/dL), erythropoietin level (100 lU/mL),
ferritin level (M), IPSS-defined risk (Int-2-risk vs. Low-/Int-
1-risk) and treatment group (lenalidomide 10 mg vs.
5 mg).
Results
Patient baseline characteristics
Of the 205 patients randomised to treatment in the MDS-
004 study, 135 (65.9%) had isolated del(5q) and were
included in the intent-to-treat population for this analysis. A
total of 47 patients were assigned to lenalidomide 10 mg, 43
to lenalidomide 5 mg and 45 to placebo. Baseline character-
istics were well balanced across treatment groups (Table 1).
Median age was 69 yr (range 36–86), 75% of patients were
female, and median time since diagnosis was 2.5 yr (range
0.2–29.2). Median haemoglobin level at baseline was 8.2 g/
dL (range 5.6–11.2), and patients had a median RBC-trans-
fusion burden of 6 units/8 wk (range 1–25). The median fol-
low-up was 35.8 months.
RBC-transfusion independence and cytogenetic
response
Rates of RBC-TI ≥182 d and cytogenetic response are pre-
sented in Table 2. The proportion of patients achieving
RBC-TI ≥182 d was significantly higher in those treated
with lenalidomide 10 mg (57.4%; P < 0.0001) or lenalido-
mide 5 mg (37.2%; P = 0.0001) compared with placebo
(2.2%). Among patients who achieved RBC-TI ≥182 d,
median time to onset of response was 4.3 wk (range
0.3–14.7) in the lenalidomide 10 mg group and 4.2 wk
(range 0.3–12.3) in the lenalidomide 5 mg group. Median
duration of RBC-TI ≥182 d response was not reached (NR)
in either lenalidomide group, but the lower boundary of the
95% confidence interval (CI) was 1.6 and 0.8 yr for lenalid-
omide 10 and 5 mg, respectively (log-rank test P = 0.8783).
Of the patients who achieved RBC–TI ≥182 d and who
were evaluable for cytogenetic response, 16 of 26 (61.5%)
in the lenalidomide 10 mg group and three of 13 (23.1%) in
the lenalidomide 5 mg group also achieved a major or minor
cytogenetic response. Median duration of RBC-TI was simi-
lar in cytogenetic responders (major + minor response) and
non-responders (NR vs. 2.0 yr, respectively; log-rank test
P = 0.4975).
Mean change in haemoglobin level from baseline over
time is shown for each treatment group in Fig. 1. Haemoglo-
bin levels increased in patients treated with lenalidomide and
reached a plateau after approximately 6 months, which was
maintained until at least month 13. In patients with RBC-TI
≥182 d, median maximum haemoglobin increases were
6.5 g/dL (range 2.0–8.7) and 5.4 g/dL (range 1.6–8.5) for
the lenalidomide 10 and 5 mg groups, respectively.
Cytogenetic response rates (major + minor responses)
were significantly higher in the lenalidomide 10 mg (56.8%;
P < 0.0001) and 5 mg (23.1%; P = 0.0299) groups com-
pared with placebo (0%; Table 2). Among these patients, 16
of 21 (76.2%) in the lenalidomide 10 mg group and three of
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six (50.0%) in the lenalidomide 5 mg group also achieved
RBC-TI ≥182 d. Of the patients who achieved a major cyto-
genetic response (lenalidomide 10 and 5 mg groups com-
bined), 11 of 16 (68.8%) also achieved RBC-TI ≥182 d.
Acute myeloid leukaemia progression
Progression to AML by randomised treatment group is pre-
sented in Fig. 2A. The estimated 2–year cumulative risk of
progression to AML was 12.6% (95%CI: 5.4–27.7), 17.4%
(95%CI: 8.7–33.3) and 16.7% (95%CI: 8.3–32.0) in the
lenalidomide 10 mg, lenalidomide 5 mg and placebo
groups, respectively. The estimated 4-yr cumulative risk of
progression to AML was 30.6% (95%CI: 18.1–48.8), 35.4%
(95%CI: 21.4–54.6) and 43.3% (95%CI: 27.6–63.1) in the
lenalidomide 10 mg, lenalidomide 5 mg and placebo groups,
respectively. Of the seven patients randomised to placebo,
who did not cross over to receive lenalidomide 5 mg in the
open-label extension phase, 3 (42.9%) progressed to AML.
In a 6-month landmark analysis, probability of AML progres-
sion was not significantly different between RBC-TI ≥182 d
responders and non-responders (log-rank test P = 0.9883;
Fig. 2B), with 2-yr AML progression rates of 7.3% (95%CI:
2.4–21.1) and 15.5% (95%CI: 6.7–33.6), respectively. Patients
who achieved a cytogenetic response (major + minor response)
had similar probabilities of AML progression compared with
Table 1 Baseline characteristics of patients with isolated del(5q) (intent-to-treat population)
Placebo
(n = 45)
LEN 5 mg
(n = 43)
LEN 10 mg
(n = 47)
Total
(N = 135)
Age, median (range), years 69 (39–85) 66 (40–84) 69 (36–86) 69 (36–86)
Female gender, n (%) 34 (75.6) 30 (69.8) 37 (78.7) 101 (74.8)
Time since diagnosis,
median (range), years
2.1 (0.2–14.3) 2.7 (0.6–13.2) 2.5 (0.2–29.2) 2.5 (0.2–29.2)
RBC-transfusion burden,
median (range), units/8 wk
6 (4–12) 7 (1–25) 6 (2–12) 6 (1–25)
IPSS risk category (central
review), n (%)
Low 29 (64.4) 20 (46.5) 20 (42.6) 69 (51.1)
Intermediate-1 9 (20.0) 16 (37.2) 13 (27.7) 38 (28.1)
Intermediate-2 1 (2.2) 2 (4.7) 1 (2.1) 4 (3.0)
Missing 6 (13.3) 5 (11.6) 13 (27.7) 24 (17.8)
French-American-British
classification (central
review), n (%)
Refractory anaemia 25 (55.6) 24 (55.8) 23 (48.9) 72 (53.3)
Refractory anaemia
with ringed sideroblasts
6 (13.3) 4 (9.3) 5 (10.6) 15 (11.1)
Refractory anaemia with
excess of blasts
3 (6.7) 8 (18.6) 6 (12.8) 17 (12.6)
Refractory anaemia with
excess of blasts in
transformation
1 (2.2) 0 0 1 (0.7)
Chronic myelomonocytic
leukaemia
1 (2.2) 1 (2.3) 0 2 (1.5)
Specimen not adequate 6 (13.3) 4 (9.3) 12 (25.5) 22 (16.3)
Other or missing 3 (6.7) 2 (4.7) 1 (2.1) 6 (4.4)
Prior erythropoietin use,
n (%)
24 (53.3) 22 (51.2) 28 (59.6) 74 (54.8)
Absolute neutrophil count,
median (range), 9109/L
2.7 (0.5–7.6) 1.8 (0.5–16.0) 2.1 (0.5–10.7) 2.1 (0.5–16.0)
Platelet count, median
(range) 9109/L
291.0 (38.0–721.0) 210.0 (33.0–1321.0) 266.0 (14.0–579.0) 253.0 (14.0–1321.0)
Haemoglobin, median
(range), g/dL
8.1 (5.6–10.5) 7.9 (5.7–10.9) 8.4 (6.2–11.2) 8.2 (5.6–11.2)
Bone marrow blast count, n (%)
<5% 32 (71.1) 28 (65.1) 27 (57.4) 87 (64.4)
≥5% 2 (4.4) 8 (18.6) 6 (12.8) 16 (11.9)
Missing 11 (24.4) 7 (16.3) 14 (29.8) 32 (23.7)
IPSS, International Prognostic Scoring System; LEN, lenalidomide; RBC, red blood cell.
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non-responders (log-rank test P = 0.6561; Fig. 2C), with 2-yr
AML progression rates of 12.4% (95%CI: 4.2–33.7) and 14.8%
(95%CI: 6.4–31.9), respectively.
Overall survival
Median OS was 4.0 yr (95%CI: 2.5–NR), 3.5 yr (95%CI:
1.7–4.8) and 2.9 yr (95%CI: 2.2–4.2) in the lenalidomide
10 mg, lenalidomide 5 mg and placebo groups, respectively
(Fig. 3A). Of the seven patients randomised to placebo who
did not cross over to lenalidomide 5 mg, 6 (85.7%) died. In
a 6-month landmark analysis, median OS was significantly
longer in patients who achieved RBC-TI ≥182 d (5.7 yr;
95%CI: 3.2–NR) compared with non-responders (2.7 yr;
95%CI: 1.5–4.8; log-rank test P = 0.0072; Fig. 3B). Median
OS was similar in patients who achieved a major or minor
cytogenetic response (4.3 yr; 95%CI: 2.3–NR) compared
with non-responders (3.7 yr; 95%CI: 2.0–4.7; log-rank test
P = 0.4073; Fig. 3C).
Univariate and multivariate analyses
In the logistic regression analysis based on patients rando-
mised to lenalidomide, patients in the lenalidomide 10 mg
group were 2.36-times more likely to achieve RBC-TI
≥182 d than those in the lenalidomide 5 mg group
(P = 0.0740; Table 3). In univariate analysis, factors associ-
ated with a significant increase in the odds of achieving
RBC-TI ≥182 d were lower RBC-transfusion burden [odds
ratio (OR) 0.84; P = 0.0275] and higher platelet count (OR
1.00; P = 0.0244); these factors were no longer significant
in the final multivariate logistic regression model after
adjusting other factors. In the Cox proportional hazards
models for OS and time to AML progression, baseline fac-
tors that negatively affected OS included advanced age
[hazard ratio (HR) 1.03; P = 0.0369] and lower platelet
count (HR 1.00; P = 0.0160) in the final multivariate
model. Baseline factors that were significantly associated
with an increased risk of progression to AML were higher
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Figure 1 Mean change (standard deviation) in
haemoglobin levels from baseline over time
by randomised treatment group in patients
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values at baseline and postbaseline. LEN,
lenalidomide.
Table 2 Response rates by randomised treatment group in patients with isolated del(5q) (intent-to-treat population)
Response
Placebo
(n = 45)
LEN 5 mg
(n = 43)
LEN 10 mg
(n = 47)
RBC-TI ≥182 d, n (%) 1 (2.2) 16 (37.2)a 27 (57.4)b
Time to onset of RBC-TI ≥182 d, median (range) weeks1 0.3 (0.3–0.3) 4.2 (0.3–12.3) 4.3 (0.3–14.7)
Duration of RBC-TI ≥182 d, median (range), years1 NR (NR–NR) NR (0.8–NR) NR (1.6–NR)
Cytogenetic response, n (%) n = 26 n = 26 n = 37
Major + minor response 0 6 (23.1)c 21 (56.8)d
Major response (no del[5q] detectable) 0 3 (11.5) 13 (35.1)
Minor response (≥50% reduction in del[5q] metaphases) 0 3 (11.5) 8 (21.6)
LEN, lenalidomide; NR, not reached; RBC-TI, red blood cell-transfusion independence.
1Responding patients only.
aP = 0.0001 vs. placebo.
bP < 0.0001 vs. placebo.
cP = 0.0299 vs. placebo.
dP < 0.0001 vs. placebo.
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RBC-transfusion burden (HR 1.12; P = 0.0180) and bone
marrow blast count ≥5% (HR 2.73; P = 0.0323).
Safety
Dose reductions due to adverse events were reported in 28
(59.6%) and 25 (58.1%) patients in the lenalidomide 10 and
5 mg groups, respectively. Adverse events led to study drug
discontinuation in 3 (6.4%), 7 (16.3%) and 2 (4.4%) patients
in the lenalidomide 10 mg, lenalidomide 5 mg and placebo
groups, respectively.
The most common grade 3–4 adverse event in patients
treated with lenalidomide was myelosuppression (Table 4).
Grade 3–4 neutropenia was reported in 35 (74.5%), 33
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(76.7%) and 7 (15.6%) patients in the lenalidomide
10 mg, lenalidomide 5 mg and placebo groups, respec-
tively, and thrombocytopenia in 18 (38.3%), 16 (37.2%)
and 1 (2.2%) patients, respectively. Grade 3–4 deep vein
thrombosis was reported in 3 (6.4%), 0 and 1 (2.2%)
patients, respectively. Patients who developed deep vein
thrombosis received antithrombotic agents. Haemorrhagic
adverse events (any grade) were reported in 12 (25.5%),
9 (20.9%) and 7 (15.6%) patients in the lenalidomide
10 mg, lenalidomide 5 mg and placebo groups, respec-
tively. Infection (any grade) was reported in 30 (63.8%),
25 (58.1%) and 13 (28.9%) patients in the lenalidomide
10 mg, lenalidomide 5 mg and placebo groups, respec-
tively.
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Figure 3 Overall survival in patients with
isolated del(5q) (intent-to-treat population) by:
(A) randomised treatment group; (B) 6-month
landmark analysis according to RBC-TI ≥182 d;
and (C) cytogenetic response (major + minor
response). *Of the 43 patients randomised to
LEN 5 mg, 25 crossed over to LEN 10 mg in
the open-label extension phase. †Of the 45
patients randomised to placebo, 38 crossed
over to LEN 5 mg in the open-label extension
phase. LEN, lenalidomide; RBC-TI, red blood
cell-transfusion independence.
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Discussion
In this MDS-004 subset analysis of patients with isolated
del(5q), lenalidomide 10 mg was associated with a rapid and
sustained achievement of RBC-TI ≥182 d in 57% of
patients. Lenalidomide treatment group (10 vs. 5 mg) was
also associated with RBC-TI ≥182 d in the logistic regres-
sion analysis; patients in the lenalidomide 10 mg group were
more likely to achieve RBC-TI ≥182 d.
Lenalidomide therapy was associated with cytogenetic
response rates (major + minor responses) of 57% in the
lenalidomide 10 mg group and 23% in the 5 mg group,
with major cytogenetic response rates of 35% and 12%,
respectively; no patients in the placebo group achieved
cytogenetic response. In addition, cytogenetic response with
lenalidomide was closely associated with RBC-TI; 76% of
the cytogenetic responders in the lenalidomide 10 mg
group and 50% in the lenalidomide 5 mg group also
achieved RBC-TI ≥182 d. The cytogenetic response rates
seen in the current analysis were lower than those reported
in MDS patients with isolated del(5q) from the MDS-003
phase 2 trial (77%), when lenalidomide 10 mg was given
on days 1–21 or 1–28 of each 28-d cycle (15). These find-
ings suggest a possible dose–response relationship between
the dose ranges studied for lenalidomide in terms of
cytogenetic response. However, it should be noted that
MDS-004 was not designed to detect differences between
the lenalidomide dose groups.
Lenalidomide therapy did not appear to have an impact on
progression to AML. However, the crossover design of the
study limits the interpretation of the data for AML progres-
sion in the different treatment groups. Similar probabilities
of AML progression were observed between patients achiev-
ing RBC-TI ≥182 d or cytogenetic response compared with
non-responders. However, the power of statistical testing in
this subset analysis was low due to the limited number of
events and patients, which makes it difficult to reach statisti-
cal significance at the 5% significance level.
Median OS was 4.0, 3.5 and 2.9 yr for the lenalidomide
10 mg, lenalidomide 5 mg and placebo groups, respectively.
Although not statistically significant, the difference in OS
among the treatment groups was consistent with the patterns
observed for cytogenetic response. The fact that a consider-
able proportion of the patients assigned to placebo (84%)
subsequently received lenalidomide as part of the open-label
extension phase may have contributed to a lack of signifi-
cance being detected across treatment groups. In a study of
untreated RBC-transfusion-dependent patients with IPSS-
defined Low- or Int-1-risk MDS and del(5q), median OS
was approximately 3.7 yr; 82% of the patients had isolated
del(5q) (5). In the same study, RBC-transfusion dependency
was associated with shorter OS (HR 2.260; P = 0.001) in a
Cox proportional hazards model of MDS patients with iso-
lated del(5q). In the current analysis, median OS was signifi-
cantly longer in patients who achieved RBC-TI ≥182 d
compared with non-responders. Although OS by cytogenetic
response was not significantly different between responders
and non-responders, this lack of significance may have been
due to the limited number of events and patients in this sub-
set analysis.
In the final multivariate analysis, younger age and higher
platelet count were significantly associated with improved
OS. In a separate Cox proportional regression model by Ger-
ming et al. (5) of untreated MDS patients with isolated del
(5q) and bone marrow blast count <5%, advanced age was
also identified as a significant factor for reduced OS
(P < 0.001). Reduced platelet counts in patients with lower-
risk MDS usually herald fibrosis, hypocellularity or more
advanced disease with increases in bone marrow blasts. It is,
therefore, understandable that patients with lower platelet
counts have worse OS than those with the typical character-
istics of the 5q syndrome, such as normal to high platelet
counts.
The incidence of adverse events appeared to be compara-
ble for patients treated with lenalidomide 10 or 5 mg. The
most common adverse events were neutropenia and throm-
bocytopenia, consistent with previous reports (15). Although
lenalidomide dose reductions were relatively common, few
patients discontinued treatment due to adverse events. In the
MDS-003 study (15), the dosing schedule was amended
from lenalidomide 10 mg daily to 10 mg for days 1–21 of
each 28-d cycle in to reduce the number of adverse events,
in particular grade 3–4 thrombocytopenia. Therefore, it is
unlikely that lenalidomide dosage increases >10 mg/d would
be implemented in future studies in an attempt to improve
cytogenetic and RBC-TI responses.
In summary, these data support the clinical benefits of
lenalidomide in the treatment of RBC-transfusion-dependent
patients with IPSS-defined Low- or Int-1-risk MDS and iso-
lated del(5q). Lenalidomide therapy was associated with a
significant achievement of RBC-TI ≥182 d and cytogenetic
response. Treatment with lenalidomide was associated with
improved OS in RBC-TI ≥182 d responders compared with
non-responders. The overall safety profile was well charac-
terised and manageable.
Table 4 Grade 3–4 adverse events reported in ≥5% of patients with
isolated del(5q) (intent-to-treat population)
n (%)
Placebo
(n = 45)
LEN 5 mg
(n = 43)
LEN 10 mg
(n = 47)
Patients with ≥1 event 19 (42.2) 40 (93.0) 45 (95.7)
Neutropenia 7 (15.6) 33 (76.7) 35 (74.5)
Thrombocytopenia 1 (2.2) 16 (37.2) 18 (38.3)
Leukopenia 0 5 (11.6) 5 (10.6)
Anaemia 3 (6.7) 3 (7.0) 2 (4.3)
Deep vein thrombosis 1 (2.2) 0 3 (6.4)
LEN, lenalidomide.
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